2014-03-17 07:48:04 - OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017 - a new market research report on companiesandmarkets.com
The uveitis market across the most important six markets, namely the US, France, Germany, Italy, Spain and the UK was valued at US$340 million in 2012. By the end of 2017, the uveitis market is forecast to be valued at US$464 million, representing a steady expansion rate over the next few years. The overall market for these six countries is forecast to increase by 6.5% CAGR.
The US market is forecast to represent the most important market sector increasing by a stronger 8.7% during the forecast period 2012 to 2017. The earlier introduction to the market of pipeline drugs compared to other markets within the European Union is forecast to drive this faster growth rate.
The major drivers of the growth of
the uveitis market over the forecast period are as follows:
The most significant driver of the growth of the uveitis market during the forecast period will be the introduction of biologics, with Humira being shifted away from off-label use to a marketed drug, and Xoma 052 being introduced as a novel biologic. This is expected to significantly change the treatment landscape for uveitis patients, and it might introduce a shift in the treatment regimen for patients with severe forms of uveitis.
While corticosteroids have been at the core of uveitis treatment, the introduction of new routes of administration for these drugs has resulted in new treatment options. Ocular implants like Retisert (fluocinolone acetonide intravitreal implant) and Ozurdex (dexamethasone intravitreal implant) have already introduced this route of administration for corticosteroids, and the pipeline product, Medidur, is expected to make ocular implants more attractive due to an expected better safety profile, long lifetime, and biodegradability. EGP-437 is a corticosteroid product for the treatment of uveitis with a novel route of administration, and is delivered into the eye using the iontophoresis technology known as the Eyegate II Delivery System (EGDS).
The pipeline drug, DE-109, is an intravitreal sirolimus injection that promises to offer a non-corticosteroid injection for the treatment of uveitis, and could potentially replace corticosteroid treatment.
Uveitis pipeline products frequently gain orphan drug status, such as DE-109 for the treatment of chronic, non-infectious uveitis, and Xoma 052 for the treatment of BehÒ«et´s disease, with uveitis being one of the hallmarks of this disease.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.